Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,890 recruiting studies in this area right now.
By phase
- Not applicable4,918
- Phase 21,185
- Phase 1582
- Phase 3465
- Phase 1/Phase 2393
- Phase 4236
- Phase 2/Phase 3111
Top conditions
- Colorectal Cancer491
- Gastric Cancer296
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Esophageal Cancer191
- Rectal Cancer176
- Breast Cancer146
- Crohn Disease144
- Ulcerative Colitis141
- Colon Cancer115
- Inflammatory Bowel Diseases108
- Hepatocellular Carcinoma (HCC)106
- Liver Cancer100
- Lung Cancer97
- Pancreas Cancer94
- Esophageal Squamous Cell Carcinoma88
- Ovarian Cancer88
- Cystic Fibrosis78
Leading sponsors
- Fudan University104
- Sun Yat-sen University90
- Mayo Clinic75
- Chinese University of Hong Kong60
- M.D. Anderson Cancer Center58
- Second Affiliated Hospital, School of Medicine, Zhejiang University57
- Assistance Publique - Hôpitaux de Paris55
- Sixth Affiliated Hospital, Sun Yat-sen University50
- National Taiwan University Hospital49
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences48
Where studies are running
- California461
- Arizona177
- Texas149
- Florida133
- Massachusetts128
- New York123
- Alabama122
- Maryland86
- Ohio80
- Pennsylvania72
Recruiting studies7,890 total
- NCT06089590Recruiting
I-CARE 2 study on IBD, cancer and serious infections
This study follows adults with Crohn's disease, ulcerative colitis, or unclassified IBD to better understand the links between these conditions, cancer, and serious infections. It asks you to share personal details and complete online surveys over time.
AmiensAges 18–75 - NCT06090110Recruiting
Vagus nerve stimulation for irritable bowel syndrome
This study tests whether a gentle electrical device that stimulates the vagus nerve can help relieve symptoms of irritable bowel syndrome. If you have IBS and are between 18 and 75, you may be able to join.
Maastricht, LimburgAges 18–75 - NCT06090656RecruitingPhase 2
Bevacizumab plus sintilimab vs TACE for liver cancer
This trial tests a combination of two drugs (bevacizumab and sintilimab) versus a standard procedure (TACE) for people with intermediate-stage liver cancer that is too large or widespread for surgery. The goal is to see if the drug combination works better at controlling the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06091423RecruitingPhase 2
XELOX plus fruquintinib and sintilimab for stomach cancer with liver or lymph node spread
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
NanjinAges 18–75 - NCT06091566Recruiting
Nerve stimulation device for overactive bladder and bowel
This study tests a new kind of nerve stimulation device that is inserted into the vagina to help control bladder and bowel problems. It may reduce urgent trips to the bathroom, leaking, and other symptoms of overactive bladder or bowel dysfunction.
AarhusAges 18 years+ - NCT06092385Recruiting
Swiss cirrhosis study for liver patients and controls
This study compares patients with advanced liver scarring (cirrhosis) to healthy controls to learn more about the condition. It may help researchers better understand and manage liver disease.
Lugano, Canton TicinoAges 18 years+ - NCT06092463Recruiting
Immune system study in newborn intestines
This study looks at how the immune system develops in the intestines of newborns, including those born early or with a blocked intestine (atresia). It may help doctors understand inflammation and improve care for sick babies.
CopenhagenAges Up to 1 year - NCT06093204Recruiting
Ultra-processed foods and eosinophilic esophagitis study
This study looks at how certain chemicals from ultra-processed foods (like packaged snacks and sodas) might trigger eosinophilic esophagitis, a food allergy condition. It will compare people with the disease to healthy volunteers of the same age and sex.
NaplesAges 3–65 - NCT06095596Recruiting
Combining vedolizumab and upadacitinib for ulcerative colitis
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
Guangzhou, GuangdongAges 18 years+ - NCT06095440Recruiting
A study on treatment results for hepatorenal syndrome
This study looks back at medical records of people who had hepatorenal syndrome (a type of kidney failure linked to liver disease) while in the hospital. The goal is to understand what treatments were used and how well patients did, which might help guide future care.
Dallas, TexasAges 18–85 - NCT06095466Recruiting
Heart check with ultrasound in severe liver disease
This study tests if a simple bedside heart ultrasound (echocardiogram) and blood tests can spot early heart problems in people with severe liver disease (cirrhosis) who are in the intensive care unit. It may help doctors better understand and manage heart complications in cirrhosis.
Sector-12, ChandigarhAges 18–65 - NCT06098417Recruiting
Fatty liver markers before weight-loss surgery
This study looks at special markers in the blood to better understand and predict a fatty liver condition called NAFLD. It focuses on people who are very overweight and are already planning to have weight-loss surgery.
TriesteAges 18–65 - NCT06098742Recruiting
Comparing a new liquid antacid to chewable Riopan in healthy adults
This trial tests whether a new liquid antacid (Antareit) works as well as the chewable Riopan tablets in healthy people. It involves a small tube placed through your nose to measure stomach acid before and after taking the medication.
MoscowAges 18–45 - NCT06099015Recruiting
Cera vascular plug study for blocking blood vessels
This study tests a device called the Cera Vascular Plug System to block blood flow in certain arteries or veins. It may help patients who need this type of treatment for conditions like abnormal blood vessels or bleeding.
Bad HersfeldAges 18–85 - NCT06099821RecruitingPhase 2
KN046 plus targeted pills for resistant MSI-H digestive cancers
This trial tests two types of targeted therapy pills (Regorafenib or Apatinib) combined with a new immunotherapy drug (KN046). It is for people with MSI-H or dMMR digestive system cancers that have stopped responding to standard immunotherapy.
BeijingAges 18 years+ - NCT06102980Recruiting
Liver stiffness test during endoscopy for fatty liver disease
This study uses an ultrasound probe during a routine endoscopy to measure liver stiffness, which can help detect liver scarring (fibrosis) in people with fatty liver disease (MASLD). If you are already scheduled for an endoscopy and have no signs of advanced liver scarring, you may be able to join.
Guayaquil, GuayasAges 18–79 - NCT06102772Recruiting
Combination immunotherapy and targeted therapy for advanced gastric cancer
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102785Recruiting
Fruquintinib plus TAS102 for advanced stomach cancer
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06104241RecruitingEarly Phase 1
Cell therapy for advanced digestive cancers
This trial tests a new cell therapy called BGT007 for people with advanced cancers of the digestive system (esophagus, stomach, pancreas, or colon) that have not responded to standard treatments. The therapy uses your own immune cells, modified to target a protein on your cancer cells.
Xuzhou, JangSuAges 18–70 - NCT06105515Recruiting
Keyhole and scope combo rescue for advanced stomach cancer
This trial tests a combined laparoscopy and endoscopy procedure as a rescue treatment for advanced stomach cancer. It is for patients who have a tumor that hasn't spread to other parts but cannot have standard stomach removal surgery.
StockholmAges 18 years+ - NCT06106269Recruiting
Outcomes of rectal artery embolization for bleeding hemorrhoids
This study looks at how well rectal artery embolization (a procedure that uses tiny particles to block blood flow to hemorrhoids) works for treating bleeding internal hemorrhoids. It aims to understand if this treatment improves quality of life and reduces symptoms.
Rochester, MinnesotaAges 18–90 - NCT06107920RecruitingPhase 3
Chemotherapy before surgery for blocked colon cancer
This trial tests whether giving chemotherapy before surgery helps people with colon cancer that caused a blockage and needed a temporary colostomy. It aims to improve outcomes compared to standard treatment.
AmiensAges 18 years+ - NCT06109272RecruitingPhase 2/Phase 3
Livmoniplimab plus Budigalimab for liver cancer
This trial tests two investigational drugs, livmoniplimab and budigalimab, given together by IV for adults with advanced liver cancer (HCC) that cannot be removed by surgery or has spread. The study aims to see if this combination shrinks tumors and helps people live longer.
Duarte, CaliforniaAges 18 years+
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,890 recruiting gastroenterology studies from the U.S. registry right now, out of 12,399 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.